法国围产期1型人类免疫缺陷病毒传播更新:5482名从受孕起持续抗逆转录病毒治疗且分娩时病毒载量检测不到的母親中零传播
该研究基于法国全国前瞻性多中心围产期队列(ANRS-EPF),纳入2000至2017年分娩的14630名1型人类免疫缺陷病毒感染妇女,评估围产期传播率。结果显示传播率从2000-2005年的1.1%降至2011-2017年的0.2%(P < .001);在受孕时即接受抗逆转录病毒治疗且分娩时血浆病毒载量检测不到的5482名母亲中,未观察到围产期传播(95%CI 0-0.07)。作者结论认为,在免费获得抗逆转录病毒治疗、每月血浆病毒载量评估、婴儿抗逆转录病毒预防且无母乳喂养的条件下,妊娠前开始并持续整个妊娠期的抑制性抗逆转录病毒治疗可将围产期1型人类免疫缺陷病毒传播降至几乎为零。
要点
- 围产期传播率从2000-2005年的1.1%(58/5123)降至2011-2017年的0.2%(10/4907),P < .001。
- 受孕时即接受抗逆转录病毒治疗者中,围产期传播从2000-2005年的0.42%(6/1434)降至2011-2017年的0.03%(1/3117),P = .007。
- 受孕时治疗且分娩时病毒载量检测不到者,围产期传播为0/5482(95%CI 0-0.07)。
核心结论
- 在免费获得抗逆转录病毒治疗、每月血浆病毒载量评估、婴儿抗逆转录病毒预防且无母乳喂养的条件下,妊娠前开始并持续整个妊娠期的抑制性抗逆转录病毒治疗可将围产期1型人类免疫缺陷病毒传播降至几乎为零。
研究设计与样本
- 全国前瞻性多中心法国围产期队列(ANRS-EPF)分析,纳入2000至2017年分娩的14630名1型人类免疫缺陷病毒感染妇女。
- 围产期传播按时间段、抗逆转录病毒治疗启动时机、母亲血浆病毒载量和出生孕周分析;无婴儿母乳喂养,所有婴儿均接受新生儿预防。
主要发现
- 围产期传播率从2000-2005年的1.1%(58/5123)降至2006-2010年的0.7%(30/4600)和2011-2017年的0.2%(10/4907),P < .001。
- 限于受孕时即接受抗逆转录病毒治疗的6316/14630(43%)名妇女,围产期传播从2000-2005年的0.42%(6/1434)降至2011-2017年的0.03%(1/3117),P = .007。
- 受孕时治疗且分娩时血浆病毒载量检测不到者,未观察到围产期传播(0/5482,95%CI 0-0.07)。
- 妊娠期间开始抗逆转录病毒治疗且分娩时血浆病毒载量检测不到者,围产期传播为0.57%(26/4596,95%CI 0.37-0.83)。
- 受孕时治疗但分娩时血浆病毒载量可检测到者,围产期传播为1.08%(9/834,95%CI 0.49-2.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretroviral therapy (ART) is remarkably effective in preventing perinatal transmission (PT) of HIV-1. We evaluated the PT rate in a population of women with widespread access to ART before conception. METHODS: The analysis included 14 630 women with HIV-1 who delivered from 2000 to 2017 at centers participating in the nationwide prospective multicenter French Perinatal Cohort (ANRS-EPF). PT was analyzed according to time period, timing of ART initiation, maternal plasma viral load (pVL), and gestational age at birth. No infants were breastfed, and all received neonatal prophylaxis. RESULTS: PT decreased between 3 periods, from 1.1% in 2000-2005 (58/5123) to 0.7% in 2006-2010 (30/4600) and to 0.2% in 2011-2017 (10/4907; P < .001). Restriction of the analysis to the 6316/14 630 (43%) women on ART at conception, PT decreased from 0.42% (6/1434) in 2000-2005 to 0.03% (1/3117) in 2011-2017 (P = .007). Among women treated at conception, if maternal pVL was undetectable near delivery, no PT was observed regardless of the ART combination [95%CI 0-0.07] (0/5482). Among women who started ART during pregnancy and with undetectable pVL near delivery, PT was 0.57% [95%CI 0.37-0.83] (26/4596). Among women treated at conception but with a detectable pVL near delivery, PT was 1.08% [95%CI 0.49-2.04] (9/834). We also qualitatively described 10 cases of transmission that occurred during the 2011-2017 period. CONCLUSIONS: In a setting with free access to ART, monthly pVL assessment, infant ART prophylaxis, and in the absence of breastfeeding, suppressive ART initiated before pregnancy and continued throughout pregnancy can reduce PT of HIV to almost zero.
引用
- Sibiude J, Le Chenadec J, Mandelbrot L, et al. Update of Perinatal Human Immunodeficiency Virus Type 1 Transmission in France: Zero Transmission for 5482 Mothers on Continuous Antiretroviral Therapy From Conception and With Undetectable Viral Load at Delivery. Clin Infect Dis. 2023. PMID: 36037040. doi:10.1093/cid/ciac703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。